Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension

Trial Profile

Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Perindopril/amlodipine (Primary) ; Amlodipine; Perindopril
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PATH
  • Most Recent Events

    • 15 Jun 2015 Results of clinical trial program (4 studies) presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 20 Nov 2012 Results published in the Media Release.
    • 20 Nov 2012 Status changed from active, no longer recruiting to completed, as reported in a XOMA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top